Drug Type Fusion protein |
Synonyms PF 06730512 |
Target |
Mechanism ROBO2 antagonists(roundabout guidance receptor 2 antagonists), SLIT2 inhibitors(slit guidance ligand 2 inhibitors), Nerve tissue proteins inhibitors(Nerve tissue proteins inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Glomerulosclerosis, Focal Segmental | Phase 2 | US | 15 Oct 2018 | |
Glomerulosclerosis, Focal Segmental | Phase 2 | JP | 15 Oct 2018 | |
Glomerulosclerosis, Focal Segmental | Phase 2 | CA | 15 Oct 2018 | |
Glomerulosclerosis, Focal Segmental | Phase 2 | CZ | 15 Oct 2018 | |
Glomerulosclerosis, Focal Segmental | Phase 2 | FR | 15 Oct 2018 | |
Glomerulosclerosis, Focal Segmental | Phase 2 | DE | 15 Oct 2018 | |
Glomerulosclerosis, Focal Segmental | Phase 2 | IT | 15 Oct 2018 | |
Glomerulosclerosis, Focal Segmental | Phase 2 | MX | 15 Oct 2018 | |
Glomerulosclerosis, Focal Segmental | Phase 2 | PL | 15 Oct 2018 | |
Glomerulosclerosis, Focal Segmental | Phase 2 | SK | 15 Oct 2018 |
Phase 2 | 47 | (PF-06730512 1000 mg IV) | jmxljozvca(syaslmefwd) = egnbkfsjyd cozcivbknu (ugmupxxpza, uiutjdoexy - yscsgkamxa) View more | - | 18 Apr 2024 | ||
(PF-06730512 300 mg IV) | jmxljozvca(syaslmefwd) = ymyxudpose cozcivbknu (ugmupxxpza, azofnfywvy - bfuetememk) View more |